28.08.2007 15:45:00
|
Harvard Bioscience President David Green to Present at Thomas Weisel Partners Healthcare Conference in Boston on September 5, 2007
Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer,
manufacturer, and marketer of a broad range of specialized products used
to advance life science research, today announced that its President,
David Green, will present at the Thomas Weisel Partners Healthcare
Conference at 9:45 am local time on Wednesday, September 5, 2007 at the
Four Seasons hotel in Boston. The presentation audio will be
simultaneously webcast and will be accessible from the HBIO website www.harvardbioscience.com
under the "Presentations & Webcasts" tab and at http://www.veracast.com/webcasts/twp/healthcare07/63104367.cfm until October 5, 2007. An archive of this presentation will also be
available on our website. Mr. Green's presentation will be available at
the conference or can be downloaded from our website by clicking on the
investor presentation icon. The presentation will cover the historical
and expected future performance of the business. There will be a
question and answer session following the presentation. Some of the
information to be presented by Mr. Green or provided in response to
questions may contain information that has not previously been
disclosed. Additionally, any material financial or other statistical
information presented in our presentation or in the question and answer
session, which has not been previously disclosed will be archived and
available in the Investor Relations section of our website.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a
broad range of specialized products, primarily scientific instruments
and apparatus, used to advance life science research at pharmaceutical
and biotechnology companies, universities and government laboratories
worldwide. HBIO sells its products to thousands of researchers in over
100 countries, through its 1,100 page catalog (and various other
specialty catalogs), its website and through its distributors, including
GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and
manufacturing operations in the United States, the United Kingdom,
Germany and Austria with additional facilities in France and Canada. For
more information, please visit www.harvardbioscience.com.
For investor inquiries, please call (508) 893-8066. Press releases may
be found on our web site, http://www.harvardbioscience.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Harvard Bioscience Inc.mehr Nachrichten
Analysen zu Harvard Bioscience Inc.mehr Analysen
Aktien in diesem Artikel
Harvard Bioscience Inc. | 2,02 | 0,00% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 403,95 | 0,97% |